atai Life Sciences Announces Results from the Kures Therapeutics Phase 1 Trial of KUR-101
Posted:
atai Life Sciences, a clinical stage biopharmaceutical company aiming to transform the treatment of mental health disorders, announced additional clinical data from the Kures Therapeutics Phase 1 trial of KUR-101 in healthy volunteers. This two-part trial was designed to assess the safety, tolerability, pharmacokinetics, and analgesic activity of KUR-101. Read more here.
The French delegation at GIANT will showcase digital tools that tackle real-world #healthcare challenges.
On Tuesday, hear their pitches on the Champion of Innovation stage from 11.45am- 12.30pm, and on the #AI Show stage from 12.45-1pm to discover how these…
Congratulations!
Our friends - Armis has successfully closed a $200 million Series D #funding round, propelling their company valuation to an impressive $4.2 billion.
Read more here.
Attendees
Sponsors and
Exhibitors
Agenda
Webinars
Contact us